Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2021 Feb 25;20(5):915–924. doi: 10.1158/1535-7163.MCT-20-0228

Figure 1: Effect of NLG207, camptothecin, and enzalutamide on cell proliferation of 22Rv1 cells.

Figure 1:

Growth of 22Rv1 cells in media containing 0.1 nM R1881 with or without 1 μM enzalutamide was evaluated over 168 hours following treatment with 10 nM NLG207 (A) or 5 nM camptothecin (B). Cell viability was determined using the Cell Counting Kit-8 cell proliferation/cytotoxicity assay at the indicated time points. The result is representative of three independent experiments. Statistical significance between groups by day 7 is denoted: **** - p<0.0001.